Can we count your visit with Google Analytics? No ads, no profiles. Details
SNSE
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
VISTA checkpoint is a differentiated immuno-oncology target with limited competition; solnerstotug could be best-in-class if Phase 1/2 data shows durable responses in checkpoint-refractory solid tumors. Multiple pipeline shots (PIKTOR, SNS-201) provide optionality.
Nano-cap size means successful data readout could be a multi-bagger.
Pre-revenue clinical-stage biotech burning cash with no approved products; ~$27M market cap implies near-term dilution risk. VISTA pathway remains largely unvalidated commercially. Pipeline is early-stage with binary trial-outcome risk on each program.
It reads our $SNSE data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.